Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study

ObjectivesMedication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropath...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2021-11, Vol.28 (e1), p.e47-e50
Hauptverfasser: Samartín-Ucha, Marisol, Pego-Reigosa, Jose Maria, Álvarez-Payero, Miriam, Martin-Vila, Alicia, Pineiro-Corrales, Guadalupe, Rodriguez-Rodriguez, Maria, Melero-Gonzalez, Rafael Benito, Maceiras-Pan, Francisco, Martinez-Reglero, Cristina, Mrtinez-Lopez de Castro, Noemi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ObjectivesMedication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropathies: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.MethodsSingle institution, descriptive, retrospective cohort study. Adult patients with chronic inflammatory arthropathies on BT between January 2009 and December 2016 were included. Persistence to BT was compared considering the type of pathology and treatment. The Kaplan–Meier test was used to analyse medication persistanence and factors associated with it. An analysis of reasons for therapy discontinuation was performed.ResultsThree hundred and sixty-two patients were included in the study, which comprised 478 BT lines. For all patients, the 12-month persistence rate was 71.3% (341 out of 478). At the end of the study, 45.2% of the patients continued on their initial BT. Median treatment persistence was 1489 days (CI 95% 1195 to 1783). Longer BT persistence was associated with naïve BT patients: 1945 days (95% CI 1523 to 2367; P
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-002133